Kimberly Eyer, a Registered Nurse with 30 years of nursing experience across diverse settings, including Home Health, ICU, Operating Room Nursing, and Research. Her roles have encompassed Operating Room Nurse, RN First Assistant, and Acting Director of a Same Day Surgery Center. Her specialty areas include Adult Cardiac Surgery, Congenital Cardiac Surgery, Vascular Surgery, and Neurosurgery.
Fact-checked by:
Victor Subia
Victor Subia
December 3, 2024
The constant bi-directional communication between microbiota and the host signifies the microbiome’s crucial role in health complications and its potential in healthcare advancements. This discussion sets the stage for exploring the microbiome’s anticipated contributions to modern medicine, particularly in addressing conditions such as endometriosis (MS), which affects approximately 200 million individuals globally. Despite centuries of […]
Kimberly Eyer, a Registered Nurse with 30 years of nursing experience across diverse settings, including Home Health, ICU, Operating Room Nursing, and Research. Her roles have encompassed Operating Room Nurse, RN First Assistant, and Acting Director of a Same Day Surgery Center. Her specialty areas include Adult Cardiac Surgery, Congenital Cardiac Surgery, Vascular Surgery, and Neurosurgery.
Fact-checked by:
Victor Subia
Victor Subia
Last Updated: December 4, 2024
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.
The constant bi-directional communication between microbiota and the host signifies the microbiome’s crucial role in health complications and its potential in healthcare advancements. This discussion sets the stage for exploring the microbiome’s anticipated contributions to modern medicine, particularly in addressing conditions such as endometriosis (EMS), which affects approximately 200 million individuals globally. Despite centuries of awareness, endometriosis remains under-recognized and inadequately treated, often resulting in delayed diagnosis, insufficient treatment, and infertility. Highlighting the necessity for improved education and advocacy, the guide aims to inform healthcare professionals about recent microbiome research advancements and their significance in enhancing endometriosis treatment outcomes.
Interplay Between Gut Microbiota and Endometriosis
The involvement of gut microbiota in EMS underscores a significant advance in understanding the etiology of this condition. Since endometriosis is estrogen-dependent, the gut microbiota’s influence on estrogen metabolism is crucial. Specifically, the estrobolome, a collective of microbial genes involved in metabolizing estrogen, appears to play a pivotal role. The estrobolome modulates estrogen levels primarily through the activity of microbial β-glucuronidases, which deconjugate estrogens into their active forms, thus influencing their systemic availability and activity.
Microbial Dysbiosis and Estrogen
The dysbiosis of the gut microbiota, particularly an increase in the Firmicutes/Bacteroidetes ratio, can exacerbate estrogen dominance. This dysregulation further stimulates the development and proliferation of endometriotic lesions. Bifidobacterium, which normally contributes to a healthy gut microbiome, is noted for its increased presence in EMS, potentially altering estrogen levels through its enzymatic activities. These findings suggest that targeting microbial dysbiosis could be a viable strategy for managing EMS.
Therapeutic Implications
Therapeutic approaches, such as the use of metronidazole targeting the Bacteroides genus, highlights the potential of modulating gut microbiota to control EMS progression. However, the restoration of lesion growth following fecal microbiota transplantation (FMT) in mice suggests a resilient, complex relationship between gut bacteria and endometriotic lesions, indicating that simply eradicating certain bacteria may not suffice. This insight leads to the hypothesis that a more nuanced understanding of the microbiota’s role in EMS could yield more effective therapies, perhaps involving a combination of probiotics, antibiotics, and estrogen-modulating drugs.
Future Directions and Research Needs
The bidirectional interaction between the host and the gut microbiota is an emerging field of study in EMS research. Future studies should aim to delineate this interaction further, perhaps exploring how dietary interventions, prebiotics, and probiotics can influence gut microbiota composition and function and, in turn, EMS symptoms. Additionally, longitudinal human studies will be crucial to verify findings observed in animal models, ensuring that therapeutic interventions are applicable and effective in human EMS patients.
Disclaimer
MicrobiomeSignatures.com is designed solely for educational and informational purposes. It is imperative to understand that the insights offered herein do not serve as substitutes for professional medical diagnosis, treatment, or advice. Readers should always seek the counsel of their physician or another qualified health provider for any questions regarding a medical condition. While every effort has been made to ensure the reliability and completeness of the information contained within this document, the evolving nature of medical knowledge and the potential for human error mean that absolute accuracy cannot be guaranteed. Consequently, the authors, editors, and publishers assume no responsibility for any discrepancies, inaccuracies, or the outcomes of applying this information.
It should be noted that certain information within this guide may be protected by copyright, a detail that may not always be explicitly acknowledged. The utilization of this guide and the application of any medical procedures discussed are undertaken at the reader’s own risk. The creators, contributors, and associated copyright holders expressly disclaim any liability for damages or losses linked to the use of the information presented herein.
Microbiome Signature
Research on the microbiome in endometriosis is ongoing, and findings regarding specific bacterial changes associated with the condition are still emerging. While there isn’t yet a comprehensive list of all reduced or increased bacteria in endometriosis, some studies have reported alterations in the abundance of certain bacterial taxa. Here’s a summary of some findings:
Bacteria
Change in Abundance
Escherichia coli (E. coli)
Increased
Enterococcus faecalis
Increased
Streptococcus species
Increased
Fusobacterium nucleatum
Increased
Lactobacillus species
Decreased
Bifidobacterium species
Decreased
Prevotella species
Decreased
It’s important to note that findings regarding bacterial alterations in endometriosis are still evolving, and additional research is needed to confirm and further elucidate these associations. Factors such as sample size, study design, and methodology can influence study outcomes, so results may vary across different studies.
FAQs
What are the Hallmarks of Endometriosis?
Here we summarize the key hallmarks of endometriosis, focusing on its clinical manifestations, pathophysiology, and implications for treatment.
Hallmark
Description
Ectopic Endometrial Tissue
Presence of tissue similar to the lining of the uterus (endometrium) outside the uterine cavity, commonly on the ovaries, fallopian tubes, and pelvic peritoneum.
Chronic Inflammation
Continuous inflammatory response surrounding ectopic lesions, contributing to the development of pain, adhesions, and tissue damage.
Pain Symptoms
Manifestations include dysmenorrhea (painful periods), chronic pelvic pain, dyspareunia (pain during intercourse), and sometimes pain with bowel movements or urination.
Infertility
Approximately 30-50% of women with endometriosis experience infertility, possibly due to inflammation, anatomical distortions, and alterations in the reproductive environment.
Hormonal Dysregulation
Estrogen dependence is a characteristic of endometriosis, with hormonal imbalances contributing to lesion growth and symptom severity.
Immune System Dysregulation
Altered immune response, including impaired clearance of ectopic endometrial cells and promotion of a pro-inflammatory environment.
Angiogenesis
Increased formation of new blood vessels supports the growth and survival of ectopic endometrial tissue.
Dysbiosis in Microbiome
Altered microbiome signatures in the gut, vagina, and peritoneal fluid, potentially contributing to the pathogenesis and symptomatology of endometriosis through inflammation and immune modulation.
Genetic and Epigenetic Factors
Genetic predisposition and epigenetic modifications influence susceptibility and disease progression, indicating a complex interplay of genetic and environmental factors.
Despite Lactobacillus spp. dominating the cervical microbiome of endometriosis patients, there was a notable increase in the abundance of Corynebacterium, Enterobacteriaceae, Flavobacterium, Pseudomonas, and Streptococcus compared to controls without endometriosis.
Real-time PCR quantification, following next-generation sequencing, confirmed that Enterobacteriaceae and Streptococcus were significantly more abundant in endometriosis patients compared to non-endometriosis controls (p > 0.05).
The cervical microbiome of endometriosis patients differed not only from healthy women but also between the early stages (I and II) and later stages (III and IV) of endometriosis.
The team proposed potential microbial biomarkers for differentiating the stages of endometriosis:
For Stages I–II: Potential biomarkers include L. jensenii, members of the Corynbacteriales, Porphyromonadaceae, and Ruminococcaceae.
For Stages III–IV: Bifidobacterium breve and members of the Streptococcaceae (e.g., Streptococcus agalactiae) were suggested as biomarkers.
FAQs
What are the Hallmarks of Endometriosis?
Here we summarize the key hallmarks of endometriosis, focusing on its clinical manifestations, pathophysiology, and implications for treatment.
Hallmark
Description
Ectopic Endometrial Tissue
Presence of tissue similar to the lining of the uterus (endometrium) outside the uterine cavity, commonly on the ovaries, fallopian tubes, and pelvic peritoneum.
Chronic Inflammation
Continuous inflammatory response surrounding ectopic lesions, contributing to the development of pain, adhesions, and tissue damage.
Pain Symptoms
Manifestations include dysmenorrhea (painful periods), chronic pelvic pain, dyspareunia (pain during intercourse), and sometimes pain with bowel movements or urination.
Infertility
Approximately 30-50% of women with endometriosis experience infertility, possibly due to inflammation, anatomical distortions, and alterations in the reproductive environment.
Hormonal Dysregulation
Estrogen dependence is a characteristic of endometriosis, with hormonal imbalances contributing to lesion growth and symptom severity.
Immune System Dysregulation
Altered immune response, including impaired clearance of ectopic endometrial cells and promotion of a pro-inflammatory environment.
Angiogenesis
Increased formation of new blood vessels supports the growth and survival of ectopic endometrial tissue.
Dysbiosis in Microbiome
Altered microbiome signatures in the gut, vagina, and peritoneal fluid, potentially contributing to the pathogenesis and symptomatology of endometriosis through inflammation and immune modulation.
Genetic and Epigenetic Factors
Genetic predisposition and epigenetic modifications influence susceptibility and disease progression, indicating a complex interplay of genetic and environmental factors.
What is the Pathophysiology of Endometriosis?
Understanding the various theories regarding the pathogenesis of endometriosis is crucial for clinicians and researchers. Below is a table summarizing the prominent theories explaining the development of endometriosis, as well as each theory’s limitations or criticisms:
Theory
Description
Limitations or Criticisms
Retrograde Menstruation Theory
Proposed by Sampson, this theory suggests that during menstruation, endometrial tissue flows backward through the fallopian tubes into the pelvic cavity instead of leaving the body, leading to the implantation and growth of endometrial cells outside the uterus.
While widely accepted, this theory does not explain why retrograde menstruation occurs in many women, but only a subset develop endometriosis. It also fails to account for cases of endometriosis in individuals without menstrual cycles, such as prepubertal girls and postmenopausal women, and in anatomical locations far from the pelvis.
Environmental Theory
Suggests that exposure to certain environmental toxins, such as dioxins, can disrupt the immune system and hormonal balance, contributing to the development of endometriosis by making the body more susceptible to implantation of ectopic endometrial cells.
Direct causal links between environmental toxins and endometriosis are difficult to establish due to confounding factors and the complexity of environmental exposures. Moreover, this theory cannot fully explain the hereditary patterns and internal physiological changes associated with the disease.
Coelomic Metaplasia Theory
Proposes that cells lining the pelvic organs (derived from the coelomic epithelium) can transform into endometrial-like cells under certain conditions, such as hormonal changes or inflammation, leading to endometriosis.
Based on the embryonic origin of reproductive organs, this theory suggests that remnants of the Müllerian ducts (precursors to female reproductive organs) may develop abnormally or be misplaced during fetal development, leading to endometriotic lesions.
Mülleriosis Theory
The mülleriosis theory struggles to explain isolated occurrences of endometriosis in males or areas unrelated to the embryonic development of the Müllerian ducts, suggesting that additional factors must be involved in disease manifestation.
The mülleriosis theory struggles to explain isolated occurrences of endometriosis in males or in areas unrelated to the embryonic development of the Müllerian ducts, suggesting that additional factors must be involved in disease manifestation.
Microbiome Theory
Posits that alterations in the microbiome, particularly in the gut and reproductive tract, can influence the immune response and create an environment conducive to the development and progression of endometriosis through inflammation and other mechanisms.
While emerging research supports the role of the microbiome in endometriosis, it is unclear whether dysbiosis is a cause or consequence of the disease. Additionally, the specific mechanisms by which microbiome alterations contribute to endometriosis development and progression remain to be fully elucidated.
Immune Dysfunction Theory
Suggests that abnormalities in the immune system prevent the body from properly identifying and destroying ectopic endometrial tissue, allowing it to implant and proliferate outside the uterus.
This theory does not explain the initial cause of immune system abnormalities and why these dysfunctions specifically lead to the development of endometriosis. Furthermore, it overlooks the role of other factors, such as hormonal influences and genetic predisposition.
Genetic and Epigenetic Theory
Indicates that genetic predisposition and epigenetic modifications play a significant role in susceptibility to endometriosis, influencing gene expression related to immune response, hormonal regulation, and cellular adhesion.
Although genetic factors undoubtedly play a role in endometriosis, this theory does not account for the environmental and acquired aspects of the disease. Moreover, specific genetic markers with high predictive value for endometriosis have yet to be identified.
Lymphovascular Metastasis Theory
Proposes that endometrial cells can spread through blood and lymphatic vessels to distant sites, explaining the occurrence of endometriosis in areas far removed from the pelvic cavity.
The lack of consistent evidence for endometrial cell survival and growth in distant vascular or lymphatic systems challenges this theory. It does not address the origin of endometriosis in areas not served by the body’s lymphovascular network.
Stem Cell Theory
Suggests that bone marrow-derived stem cells or stem-like cells from the endometrium may contribute to the formation of endometriotic lesions through differentiation and proliferation at ectopic sites.
While promising, the stem cell theory requires further evidence to clarify how stem cells from bone marrow or the endometrium contribute to endometriosis. It also does not fully explain the localized inflammatory and hormonal environment that fosters lesion development.
While the retrograde menstruation theory is the prevailing theory, these criticisms underscore the complexity of endometriosis and suggest that no single theory can comprehensively account for all aspects of the disease. Endometriosis likely results from a combination of factors, and a multifactorial model that integrates several of these theories may offer a more accurate and plausible explanation for the pathogenesis of endometriosis.
In short, the integration of these theories and their criticisms underscores the importance of continued research and the potential need for a combined or new theoretical framework to elucidate the pathophysiology of endometriosis fully.
What is the role of Beta-glucuronidase in Endometriosis?
Beta-glucuronidase is an enzyme produced by various bacterial species, including some of those mentioned earlier. Specifically, Escherichia coli (E. coli) and Enterococcus faecalis are known to produce beta-glucuronidase. This enzyme is involved in the metabolism of glucuronides, which are conjugated forms of various compounds, including estrogens. In the context of endometriosis, the activity of beta-glucuronidase may play a role in the reactivation of estrogen within the gastrointestinal tract, potentially contributing to hormonal dysregulation associated with the condition.
Update History
2024-12-03 06:32:07
Pdf major
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Endometriosis involves ectopic endometrial tissue causing pain and infertility. Validated and Promising Interventions include Hyperbaric Oxygen Therapy (HBOT), Low Nickel Diet, and Metronidazole therapy.
Endometriosis
Endometriosis involves ectopic endometrial tissue causing pain and infertility. Validated and Promising Interventions include Hyperbaric Oxygen Therapy (HBOT), Low Nickel Diet, and Metronidazole therapy.
Infertility
Infertility is the inability to conceive after 12 months of regular, unprotected sex. It affects both men and women and can be due to various physical, hormonal, or genetic factors. Treatments include medication, surgery, assisted reproductive technologies, and lifestyle changes.
Estrobolome
The estrobolome is a group of gut bacteria that metabolize estrogen, impacting its levels and effects in the body. By modulating estrogen reabsorption and excretion, the estrobolome influences hormonal balance and risks of estrogen-related conditions, making it a target for therapeutic interventions.
Fecal Microbiota Transplantation (FMT)
Fecal Microbiota Transplantation (FMT) involves transferring fecal bacteria from a healthy donor to a patient to restore microbiome balance.
Kimberly Eyer, a Registered Nurse with 30 years of nursing experience across diverse settings, including Home Health, ICU, Operating Room Nursing, and Research. Her roles have encompassed Operating Room Nurse, RN First Assistant, and Acting Director of a Same Day Surgery Center. Her specialty areas include Adult Cardiac Surgery, Congenital Cardiac Surgery, Vascular Surgery, and Neurosurgery. 
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study. 
Overview 
Microbiome Signature 
FAQs 
Research Feed 
Update History 
References